文献速递鼻科咽喉与嗓音

孟鲁司特联合布地奈德与单用布地奈德治疗过敏性鼻炎的随机试验

A Randomized Trial of Comparing a Combination of Montelukast and Budesonide With Budesonide in Allergic Rhinitis.
PubMed 文献 · Laryngoscope · 2019-11-29

这项单中心随机开放标签研究纳入46例季节性过敏性鼻炎患者,比较布地奈德(256 μg)联合孟鲁司特(10 mg)与单用布地奈德治疗2周的疗效。结果显示联合治疗在改善鼻塞、鼻痒方面优于单药,且能更显著降低FeNO浓度并改善鼻腔容积,提示联合治疗对鼻部症状和亚临床下气道炎症可能更有效。

要点

  • 联合治疗在改善鼻塞和鼻痒方面显著优于单用布地奈德。
  • 联合治疗可显著改善鼻腔容积并降低FeNO浓度。
  • 鼻塞评分与鼻腔容积和鼻阻力显著相关。

核心结论

  • 布地奈德联合孟鲁司特治疗季节性过敏性鼻炎可能整体疗效优于单用布地奈德,尤其在改善鼻塞、鼻痒和亚临床下气道炎症方面。

研究设计与样本

  • 单中心、随机、开放标签研究,纳入46例季节性过敏性鼻炎患者,随机接受布地奈德(256 μg)联合孟鲁司特(10 mg)或单用布地奈德(256 μg)治疗2周。

主要发现

  • 两种治疗均显著改善5项主要季节性过敏性鼻炎症状,但联合治疗对鼻塞和鼻痒的改善显著优于单药。
  • 治疗2周后,联合治疗显著改善鼻腔容积,但未显著改善鼻阻力,且改善程度优于单药。
  • 基线FeNO浓度≥30 ppb的患者数量在联合治疗后显著减少,单药治疗后未显著减少。
  • 联合治疗导致FeNO浓度下降的幅度显著大于单药治疗。

关键数值与推荐

  • 布地奈德剂量为256 μg,孟鲁司特剂量为10 mg,疗程2周。
  • FeNO浓度阈值定义为30 ppb。

临床怎么用

  • 对于季节性过敏性鼻炎患者,可考虑布地奈德联合孟鲁司特以更有效改善鼻塞和鼻痒。
  • 鼻腔容积和鼻阻力可用于更准确评估鼻塞。
  • 联合治疗可能有助于改善亚临床下气道炎症。

局限性

  • 单中心、开放标签设计可能引入偏倚。
  • 样本量较小(46例),结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: It is not unequivocally proven whether a combination of an intranasal corticosteroids (INSs) and a cysteinyl leukotriene receptor antagonist has greater efficacy than INSs in the treatment of seasonal allergic rhinitis (SAR). STUDY DESIGN: Single-center, randomized, open-label study. METHODS: Study subjects included 46 participants with SAR. Participants were randomized to receive budesonide (BD; 256 μg) plus montelukast (MNT; 10 mg) (BD + MNT) or BD alone (256 μg) for 2 weeks. Visual analog scale scores for five major symptoms of SAR, nasal cavity volume (NCV), nasal airway resistance (NAR), and fractional exhaled nitric oxide (FeNO) were assessed before and at the end of treatments. RESULTS: Both treatments significantly improved the five main SAR symptoms from baseline; however, BD + MNT produced significantly greater improvements in nasal blockage and nasal itching compared to BD alone. At baseline, the nasal blockage score was significantly correlated with NCV and NAR (r = -0.473, P = .002 and r = -0.383, P = .013, respectively). After 2 weeks of treatment, BD + MNT significantly improved NCV, but not NAR, to a greater level than BD. The number of patients with FeNO concentration ≥ 30 ppb at baseline was significantly decreased after BD + MNT treatment, but not after BD treatment. Similarly, BD + MNT treatment led to a significantly greater decrease in FeNO concentration than BD treatment. CONCLUSIONS: BD + MNT treatment may have an overall superior efficacy than BD monotherapy for patients with SAR, especially in improvement of nasal blockage, itching, and subclinical lower airway inflammation. Also, NCV and NAR could be used to assess nasal blockage more accurately. LEVEL OF EVIDENCE: 1b Laryngoscope, 131:E1054-E1061, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Chen H, Zhang L, Lou H, et al. A Randomized Trial of Comparing a Combination of Montelukast and Budesonide With Budesonide in Allergic Rhinitis. Laryngoscope. 2019. PMID: 31782814. doi:10.1002/lary.28433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。